BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

545 related articles for article (PubMed ID: 22290256)

  • 1. Individualized targeted therapy for glioblastoma: fact or fiction?
    Weller M; Stupp R; Hegi M; Wick W
    Cancer J; 2012; 18(1):40-4. PubMed ID: 22290256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy for glioblastoma: current treatment and future perspectives for cytotoxic and targeted agents.
    Minniti G; Muni R; Lanzetta G; Marchetti P; Enrici RM
    Anticancer Res; 2009 Dec; 29(12):5171-84. PubMed ID: 20044633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Personalized oncology: recent advances and future challenges.
    Kalia M
    Metabolism; 2013 Jan; 62 Suppl 1():S11-4. PubMed ID: 22999010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment outcomes for patients with glioblastoma multiforme and a low Karnofsky Performance Scale score on presentation to a tertiary care institution. Clinical article.
    Marina O; Suh JH; Reddy CA; Barnett GH; Vogelbaum MA; Peereboom DM; Stevens GH; Elinzano H; Chao ST
    J Neurosurg; 2011 Aug; 115(2):220-9. PubMed ID: 21548745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Personalized medicine in neurosurgery.
    Nicolaidis S
    Metabolism; 2013 Jan; 62 Suppl 1():S45-8. PubMed ID: 23018147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort.
    Metellus P; Coulibaly B; Nanni I; Fina F; Eudes N; Giorgi R; Barrie M; Chinot O; Fuentes S; Dufour H; Ouafik L; Figarella-Branger D
    Cancer; 2009 Oct; 115(20):4783-94. PubMed ID: 19637364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New chemotherapy options for the treatment of malignant gliomas.
    Soffietti R; Rudà R; Trevisan E
    Anticancer Drugs; 2007 Jul; 18(6):621-32. PubMed ID: 17762390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New molecularly targeted therapies for glioblastoma multiforme.
    Polivka J; Polivka J; Rohan V; Topolcan O; Ferda J
    Anticancer Res; 2012 Jul; 32(7):2935-46. PubMed ID: 22753758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of molecular biomarkers for predicting the response to radiotherapy with or without chemotherapy.
    Riesterer O; Milas L; Ang KK
    J Clin Oncol; 2007 Sep; 25(26):4075-83. PubMed ID: 17827456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma.
    Weller M; Müller B; Koch R; Bamberg M; Krauseneck P;
    J Clin Oncol; 2003 Sep; 21(17):3276-84. PubMed ID: 12947063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology].
    Ludwig WD
    Z Evid Fortbild Qual Gesundhwes; 2012; 106(1):11-22. PubMed ID: 22325103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Challenge of Developing New Therapies for Childhood Cancers.
    Balis FM
    Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypericin uptake: a prognostic marker for survival in high-grade glioma.
    Ritz R; Müller M; Dietz K; Duffner F; Bornemann A; Roser F; Tatagiba M
    J Clin Neurosci; 2008 Jul; 15(7):778-83. PubMed ID: 18394904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel medical therapeutics in glioblastomas, including targeted molecular therapies, current and future clinical trials.
    Quant EC; Wen PY
    Neuroimaging Clin N Am; 2010 Aug; 20(3):425-48. PubMed ID: 20708556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing radiotherapy schedules for elderly glioblastoma multiforme patients.
    Clarke JW; Chang EL; Levin VA; Mayr NA; Hong E; Cavaliere R; Lo SS
    Expert Rev Anticancer Ther; 2008 May; 8(5):733-41. PubMed ID: 18471046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients.
    Felsberg J; Rapp M; Loeser S; Fimmers R; Stummer W; Goeppert M; Steiger HJ; Friedensdorf B; Reifenberger G; Sabel MC
    Clin Cancer Res; 2009 Nov; 15(21):6683-93. PubMed ID: 19861461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The 'Sentinel Node' Concept: More Questions Raised than Answers Provided?
    Schlag PM
    Oncologist; 1998; 3(5):VI-VII. PubMed ID: 10388128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular diagnostics of gliomas: the clinical perspective.
    Tabatabai G; Stupp R; van den Bent MJ; Hegi ME; Tonn JC; Wick W; Weller M
    Acta Neuropathol; 2010 Nov; 120(5):585-92. PubMed ID: 20862485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New developments in the treatment of malignant gliomas.
    Soffietti R; Leoncini B; Rudà R
    Expert Rev Neurother; 2007 Oct; 7(10):1313-26. PubMed ID: 17939769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular advances of brain tumors in radiation oncology.
    Noda SE; El-Jawahri A; Patel D; Lautenschlaeger T; Siedow M; Chakravarti A
    Semin Radiat Oncol; 2009 Jul; 19(3):171-8. PubMed ID: 19464632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.